| Previous Close | 0.1050 |
| Open | 0.1050 |
| Bid | 0.1000 x 0 |
| Ask | 0.1000 x 0 |
| Day's Range | 0.1000 - 0.1100 |
| 52 Week Range | 0.0300 - 0.1600 |
| Volume | 1,309,660 |
| Avg. Volume | 2,758,588 |
| Market Cap | 18.273M |
| Beta (5Y Monthly) | 2.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0120 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- CNW Group
IIROC Trading Halt - ICO
VANCOUVER, BC, March 22, 2021 /CNW/ - The following issues have been halted by IIROC: Company: iCo Therapeutics Inc.TSX-Venture Symbol: ICO All Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 7:46 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.
- Newsfile
iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo") and Satellos Bioscience Inc. ("Satellos"), a private Canadian corporation, together are pleased to announce the execution of a definitive agreement, dated March 21, 2021 (the "Arrangement Agreement"), providing for the business combination of iCo and Satellos by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act (the ...
- Newsfile
iCo Therapeutics, Inc. Announces Agreement for in Vivo Testing of iCo-019 on SARS-CoV-2
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2, the causative agent of COVID-19 in the hACE2 mouse model (the "iCo-019 Study"). iCo anticipates that the iCo-019 ...
